| dc.contributor.author | Matur, Zeliha | |
| dc.contributor.author | Parman, Yesim Gulsen | |
| dc.date.accessioned | 2021-03-03T14:45:04Z | |
| dc.date.available | 2021-03-03T14:45:04Z | |
| dc.identifier.citation | Matur Z., Parman Y. G. , "Use of Botulinum Toxin Type a in the Treatment of Spasticity", NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.47, ss.40-43, 2010 | |
| dc.identifier.issn | 1300-0667 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_3b3a662d-8408-4553-8024-2ebac16b9060 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/43784 | |
| dc.identifier.uri | https://doi.org/10.4274/npa.y5929 | |
| dc.description.abstract | Spasticity is a component of the upper motor neuron syndrome and occurs after maladaptive improvement. Velocity-dependent increase in muscle tonus causes restricted movement, muscle shortness, pain, joint malpositions and contractures. When spasticity is harmful, it has to be treated. The treatment of spasticity requires a multidisciplinary approach. Botulinum toxin type A is effective when used with other treatment modalities, especially with physiotherapy. (Archives of Neuropsychiatry 2010; 47 Supplement: 40-3) | |
| dc.language.iso | eng | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Nöroloji | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | KLİNİK NEUROLOJİ | |
| dc.title | Use of Botulinum Toxin Type a in the Treatment of Spasticity | |
| dc.type | Makale | |
| dc.relation.journal | NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY | |
| dc.contributor.department | İstanbul Üniversitesi , , | |
| dc.identifier.volume | 47 | |
| dc.identifier.startpage | 40 | |
| dc.identifier.endpage | 43 | |
| dc.contributor.firstauthorID | 194377 | |
